Latest Period
Q2 2026
Security Snapshot
NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) Institutional Ownership
CUSIP: 44975P103
13F Institutional Holders and Ownership History from Q1 2020 to Q2 2026
Institutions Reporting
27
Shares (Excl. Options)
8,304,318
Price
$1.95
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
- Symbol
- NBP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 8,304,318
- Total 13F value
- $16,195,375
- Portfolio coverage rank
- 0%
- Share change
- +2,080,125
- Value change
- +$3,926,396
- Number of holders
- 27
- Shares outstanding
- 265,214,861
- SEC-reported price per share
- $1.90
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NBP - NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) is tracked under CUSIP 44975P103.
- 27 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 47 to 27 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $72,073,173 to $16,195,375.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 27 institutions filings for Q2 2026.
Security key
44975P103
Latest holder period
Q2 2026
13F holders
27
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
NBP full holder history
NovaBridge Biosciences SEC filings
NovaBridge Biosciences company facts
NovaBridge Biosciences insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 44975P103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
NBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Everest Medicines Ltd | 16% | $90,577,645 | 42,524,716 | Everest Medicines Limited | 05 Aug 2025 | |||
| CBC Investment I-Mab Ltd | 12% | +11% | $121,227,193 | +$11,952,376 | 30,499,709 | +11% | Wei Fu | 29 Jan 2026 |
As of 30 Jun 2026, 27 institutional investors reported holding 8,304,318 shares of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP). This represents 3.1% of the company’s total 265,214,861 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q2 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 8,304,318 | $16,195,375 | +$3,926,396 | $1.95 | 27 |
| 2026 Q1 | 29,315,624 | $72,073,173 | -$13,543,670 | $2.46 | 47 |
| 2025 Q4 | 33,200,810 | $132,139,164 | +$14,644,437 | $3.98 | 57 |
| 2025 Q3 | 29,690,135 | $112,309,052 | +$77,501,715 | $3.78 | 42 |
| 2025 Q2 | 9,395,986 | $22,737,366 | +$2,030,864 | $2.42 | 32 |
| 2025 Q1 | 8,993,007 | $7,408,233 | -$2,236,666 | $0.82 | 29 |
| 2024 Q4 | 11,912,678 | $10,125,354 | -$4,196,499 | $0.85 | 27 |
| 2024 Q3 | 14,193,703 | $17,600,522 | -$1,644,775 | $1.24 | 27 |
| 2024 Q2 | 15,140,525 | $25,329,475 | +$4,917,141 | $1.67 | 37 |
| 2024 Q1 | 12,194,479 | $22,682,620 | -$591,267 | $1.86 | 38 |
| 2023 Q4 | 12,343,395 | $23,450,292 | -$3,932,021 | $1.90 | 43 |
| 2023 Q3 | 15,251,229 | $20,128,696 | -$8,412,218 | $1.32 | 46 |
| 2023 Q2 | 18,691,045 | $55,880,438 | -$6,382,969 | $2.99 | 46 |
| 2023 Q1 | 20,700,388 | $71,623,449 | -$16,502,335 | $3.46 | 51 |
| 2022 Q4 | 24,863,205 | $103,919,915 | -$23,835,362 | $4.18 | 63 |
| 2022 Q3 | 30,756,340 | $123,319,030 | -$78,451,098 | $4.01 | 69 |
| 2022 Q2 | 38,195,150 | $430,214,056 | -$43,072,457 | $11.30 | 91 |
| 2022 Q1 | 40,274,792 | $654,272,172 | -$2,809,989 | $16.24 | 112 |
| 2021 Q4 | 39,063,350 | $1,843,596,654 | +$49,692,681 | $47.39 | 127 |
| 2021 Q3 | 36,035,033 | $2,613,664,389 | +$445,184,584 | $72.49 | 140 |
| 2021 Q2 | 28,287,880 | $2,375,233,906 | +$495,487,800 | $83.95 | 133 |
| 2021 Q1 | 23,316,491 | $1,130,077,433 | +$490,958,954 | $48.47 | 78 |
| 2020 Q4 | 13,056,509 | $615,418,000 | +$200,018,636 | $47.15 | 63 |
| 2020 Q3 | 9,526,320 | $447,661,000 | +$236,962,427 | $47.03 | 48 |
| 2020 Q2 | 3,298,968 | $97,724,000 | -$2,617,263 | $29.93 | 19 |